EW · CIK 0001099800
What Edwards Lifesciences Corporation told the SEC could break it.
Edwards' biggest flag is product concentration: its TAVR heart-valve products were 74% of net sales in 2025, so competition, pricing pressure or a clinical or regulatory setback in that one line would weigh heavily on the company. The rest reflects the specialized nature of its manufacturing and market — most of its replacement valves are made from natural animal tissue, it buys certain supplies from single sources because of sole-source availability or regulatory constraints, and its pricing and market access face government and private cost-containment, reimbursement and comparative-effectiveness pressures across the U.S., Europe and Japan.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- TAVR product-line revenue concentration (74% of net sales)high
Edwards' revenue is heavily concentrated in its TAVR products, which represented 74% of net sales in 2025 (75% in 2024, 77% in 2023) — exposing the company to TAVR competition, pricing, and clinical/regulatory setbacks.
“Sales of our TAVR products represented 74%, 75%, and 77% of our net sales in 2025, 2024, and 2023, respectively.”
SEC filing →As of 2026
Commodity & input dependence
- natural animal tissue for bioprosthetic heart valvesmedium
Most of Edwards' replacement heart valves are manufactured from natural tissues harvested from animal tissue, making the company dependent on a specialized biological raw-material supply.
“Most of our replacement heart valves are manufactured from natural tissues harvested from animal tissue as well as fabricated materials. We purchase certain materials and components used in manufacturing our products from external suppliers.”
SEC filing →As of 2026
Regulatory & policy
- healthcare cost-containment, reimbursement and price regulationmedium
Government and private cost-containment initiatives — price regulation, coverage/payment policies, comparative-effectiveness reviews, and increasing evidentiary demands across the U.S., Europe, and Japan — pressure Edwards' pricing and market access.
“Government and private sector initiatives to limit the growth of health care costs, including price regulation and competitive pricing, coverage and payment policies, comparative effectiveness reviews, technology assessments, increasing evidentiary demands, and managed-care arrangements, are continuing in many geographies where we do business, including the United States, Europe, and Japan.”
SEC filing →As of 2026
Sole-source dependency
- single-source supplies (sole-source availability / regulatory constraints), unnamedmedium
Edwards purchases certain supplies from single sources due to sole-source availability or regulatory constraints, creating supply-continuity risk if those relationships are disrupted.
“In addition, we purchase certain supplies from single sources for reasons of sole source availability or constraints resulting from regulatory requirements. We work with our suppliers to mitigate risk and seek continuity of supply while maintaining quality and reliability.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch